Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Neuron
Authors
Keywords
Abstract

To identify novel genes associated with ALS, we undertook two lines of investigation. We carried out a genome-wide association study comparing 20,806 ALS cases and 59,804 controls. Independently, we performed a rare variant burden analysis comparing 1,138 index familial ALS cases and 19,494 controls. Through both approaches, we identified kinesin family member 5A (KIF5A) as a novel gene associated with ALS. Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia (SPG10) and Charcot-Marie-Tooth type 2 (CMT2). In contrast, ALS-associated mutations are primarily located at the C-terminal cargo-binding tail domain and patients harboring loss-of-function mutations displayed an extended survival relative to typical ALS cases. Taken together, these results broaden the phenotype spectrum resulting from mutations in KIF5A and strengthen the role of cytoskeletal defects in the pathogenesis of ALS.

Year of Publication
2018
Journal
Neuron
Volume
97
Issue
6
Pages
1268-1283.e6
Date Published
2018 03 21
ISSN
1097-4199
DOI
10.1016/j.neuron.2018.02.027
PubMed ID
29566793
PubMed Central ID
PMC5867896
Links
Grant list
ZIA AG000933-03 / ImNIH / Intramural NIH HHS / United States
G0600974 / MRC_ / Medical Research Council / United Kingdom
TURNER/JAN13/944-795 / MNDA_ / Motor Neurone Disease Association / United Kingdom
MALASPINA/APR13/817-791 / MNDA_ / Motor Neurone Disease Association / United Kingdom
SHAW/APR15/933-794 / MNDA_ / Motor Neurone Disease Association / United Kingdom
G0900688 / MRC_ / Medical Research Council / United Kingdom
MR/L016397/1 / MRC_ / Medical Research Council / United Kingdom
SHAW/NOV14/985-797 / MNDA_ / Motor Neurone Disease Association / United Kingdom
K25 HL121295 / HL / NHLBI NIH HHS / United States
U54 NS091046 / NS / NINDS NIH HHS / United States
MR/K01014X/1 / MRC_ / Medical Research Council / United Kingdom
ALCHALABI-DOBSON/APR14/829-791 / MNDA_ / Motor Neurone Disease Association / United Kingdom
P50 AG005146 / AG / NIA NIH HHS / United States
MR/L501529/1 / MRC_ / Medical Research Council / United Kingdom
P01 AG017586 / AG / NIA NIH HHS / United States
R56 NS061867 / NS / NINDS NIH HHS / United States
U54 NS092091 / NS / NINDS NIH HHS / United States
R35 NS097261 / NS / NINDS NIH HHS / United States
R01 MD009164 / MD / NIMHD NIH HHS / United States
R01 NS061867 / NS / NINDS NIH HHS / United States
P30 AG013846 / AG / NIA NIH HHS / United States
I01 BX002466 / BX / BLRD VA / United States
MR/M008606/1 / MRC_ / Medical Research Council / United Kingdom
R01 NS073873 / NS / NINDS NIH HHS / United States
MCLAUGHLIN/OCT15/957-799 / MNDA_ / Motor Neurone Disease Association / United Kingdom
MR/L021803/1 / MRC_ / Medical Research Council / United Kingdom
K23 ES027221 / ES / NIEHS NIH HHS / United States
FRATTA/JAN15/946-795 / MNDA_ / Motor Neurone Disease Association / United Kingdom
G0500289 / MRC_ / Medical Research Council / United Kingdom
Z01 AG000949 / ImNIH / Intramural NIH HHS / United States
SMITH/APR16/847-791 / MNDA_ / Motor Neurone Disease Association / United Kingdom
MC_PC_17115 / MRC_ / Medical Research Council / United Kingdom
P01 NS084974 / NS / NINDS NIH HHS / United States
MR/R024804/1 / MRC_ / Medical Research Council / United Kingdom
WT_ / Wellcome Trust / United Kingdom
SMITH/OCT16/888-792 / MNDA_ / Motor Neurone Disease Association / United Kingdom